Payne Christopher D 4

What Happened Christopher D. Payne, a director of Hims & Hers Health, Inc. (HIMS), was granted 647 restricted stock units (RSUs) on 2026-05-20 as director compensation. The Form 4 records the acquisition price as $0.00 (derivative award), and the company valued the foregone cash fees at $14,875 using a grant price of $22.98 per share to calculate the RSU count. The RSUs represent a contingent right to one share of Class A common stock per RSU and will vest in full on the company's next quarterly vesting date.

Key Details

• Transaction date: 2026-05-20 (reported on Form 4 filed 2026-05-22).
• Award: 647 RSUs; grant valuation basis $22.98/share → total ≈ $14,875; Form 4 shows acquisition price $0.00 because these are derivative awards.
• Shares owned after transaction: Not specified in the provided filing.
• Footnotes: RSUs convert 1:1 to Class A common shares upon vesting; issued under the Issuer's Director Compensation Policy in lieu of Q1 2026 cash retainer/committee fees.
• Timeliness: Filing date (5/22) is two days after the transaction date (5/20), which appears to be timely under Form 4 rules.

Context RSU grants to directors are routine compensation and are derivative until they vest (they do not represent immediately tradable shares). This award reflects compensation in lieu of cash retainer rather than an open-market purchase or sale, so it should be viewed as routine compensation activity rather than an expressed market sentiment by the director.